D4+DISINFECTANT SOLUTION

Indications

• Warts
• Plantar warts
• Verrucas
• Umbilical granulomas

Dosage

Children: Apply twice daily for up to 3 consecutive days. Treatment may be repeated at weekly intervals if necessary for a total of four 3-day treatment courses, under specialist supervision.

Adults: Apply twice daily to the lesion for a maximum of 3 applications. Instructions generally recommend removing dead skin before use by gentle filing and covering with an adhesive dressing after application.

Mechanism of action

Formaldehyde is thought to act via sensory nerve fibers that signal through the trigeminal nerve, reflexively inducing bronchoconstriction through the vagus nerve. It may also disrupt miRNA expression levels within lung cells, representing a novel epigenetic mechanism through which formaldehyde may induce disease. Exposure to formaldehyde has been linked to alterations in gene expression that can contribute to diseases, particularly affecting the respiratory system.

Pharmacodynamics

Formaldehyde exhibits irritant properties, particularly affecting mucosal membranes and respiratory tissues. Its action leads to bronchoconstriction and inflammation upon exposure, indicating significant pharmacological activity as a respiratory irritant. Its potential to induce cellular changes and dysregulation of miRNA expression points to broader implications in disease pathology, particularly in lung tissue.

Pharmacokinetics

Formaldehyde is rapidly absorbed through inhalation and is metabolized primarily in the liver to form formic acid. Its short half-life and high reactivity limit its systemic exposure. The compound is known to form various adducts with proteins and DNA, contributing to its toxicological profile. Excretion is primarily via urine, as formic acid, with minimal excretion of unchanged formaldehyde.

Contra-indications

• Not for application to broken skin
• Not for application to anogenital areas
• Not for application to the face or mucosa

Adverse effects

• Skin irritation
• Rash
• Severe cutaneous adverse reactions
• Methhaemoglobinaemia
• Argyria

Precautions

• Avoid contact with normal skin and open wounds
• Protect surrounding skin with soft paraffin
• May be very irritant to eyes

Pregnancy

Avoid use during pregnancy due to potential harmful effects.

Breast-feeding

Avoid use during breastfeeding due to potential harmful effects.

Storage

Store in a cool, dry place away from light.

Formulations

• Formaldehyde solution 4% (Buffered)
• Formaldehyde liquid 10%

Indications

• Warts, particularly plantar warts
• Condylomata acuminata affecting the penis or female external genitalia
• Sterilization of medical instruments

Dosage

Children: For children aged 2–17 years (initiated under specialist supervision), apply twice daily for 3 consecutive days. Treatment may be repeated at weekly intervals if necessary for a total of four 3-day courses.

Adults: Apply twice daily to the lesion for up to 3 applications, ensuring to remove dead skin before use. Treatment may be repeated weekly if necessary.

Mechanism of action

Glutaraldehyde functions primarily by cross-linking with proteins and nucleic acids, leading to microbial cell death. This cross-linking interferes with the normal functioning of cellular components, thereby disrupting metabolism and replication in bacteria, viruses, and fungi.

Pharmacodynamics

The pharmacodynamic profile of glutaraldehyde is characterized by its rapid action as a broad-spectrum antimicrobial agent. It exhibits bactericidal, virucidal, and fungicidal properties, making it effective against a wide range of pathogens, including resistant strains. Its activity is influenced by concentration, exposure time, and pH levels, with higher concentrations and longer exposure times enhancing its antimicrobial effects.

Pharmacokinetics

Glutaraldehyde is primarily used topically and does not have significant systemic absorption when applied appropriately. It is rapidly metabolized and eliminated from the body. The exact pharmacokinetic parameters, such as half-life or volume of distribution, are not well characterized due to its topical use and rapid inactivation upon contact with tissues.

Contra-indications

• Not for application to anogenital areas
• Not for application to the face
• Not for application to mucosa
• Avoid broken skin

Adverse effects

• Skin irritation
• Rash
• Balanoposthitis
• Severe cutaneous adverse reactions
• Argyria
• Methaemoglobinaemia

Precautions

• Avoid application to normal skin
• Avoid open wounds
• Keep away from eyes
• Use under specialist supervision for children

Pregnancy

Avoid use during pregnancy.

Breast-feeding

Avoid use during breastfeeding.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Warticon 0.5% solution
• Glutaraldehyde liquid

Indications

• Disinfection of surfaces
• Antisepsis of skin
• Preservative in pharmaceutical formulations
• Sanitizing agent in personal care products

Dosage

Children: Refer to specific product guidelines or institutional protocols for appropriate dosing and application methods.

Adults: Refer to specific product guidelines or institutional protocols for appropriate dosing and application methods.

Mechanism of action

Benzalkonium chloride acts by disrupting the cell membrane of bacteria and other microorganisms. Its positively charged quaternary ammonium structure interacts with the negatively charged components of microbial cell membranes, leading to cell lysis. This mechanism results in the inhibition of microbial growth and eventual cell death.

Pharmacodynamics

Benzalkonium chloride exhibits bactericidal and fungicidal activity. It is effective against Gram-positive and Gram-negative bacteria, as well as some viruses and fungi. The concentration of the solution determines its action, with higher concentrations leading to more rapid and complete microbial destruction. It does not typically have residual antibacterial activity, as it does not penetrate deeply into tissues.

Pharmacokinetics

Benzalkonium chloride's systemic absorption is minimal when applied topically, and it is not significantly absorbed through intact skin. It is primarily eliminated through the liver and kidneys, with metabolites excreted in urine. The compound's half-life and distribution can vary depending on the formulation and route of administration.

Adverse effects

• Skin irritation
• Allergic reactions
• Respiratory distress
• Eye irritation
• Gastrointestinal disturbances

Precautions

• Avoid contact with eyes and mucous membranes
• Use with caution in individuals with known allergies to quaternary ammonium compounds
• Not for ingestion

Pregnancy

There is limited data on the use of alkyldimethylbenzylammonium during pregnancy. Use only if clearly needed and benefits outweigh risks.

Breast-feeding

Caution is advised when using alkyldimethylbenzylammonium while breastfeeding due to limited data on excretion in milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Liquid disinfectants
• Surface cleaners
• Hand sanitizers
• Wipes

Dosage

Children: Refer to the BNF for Children for paediatric dosing information.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Glyoxal attacks the amino groups of proteins, nucleotides, and lipids due to its highly reactive carbonyl groups. This initiates glycation, a series of non-enzymatic reactions that produce stable AGEs. Glyoxal forms stable adducts with guanosine by reacting with the N-1 and exocyclic nitrogen of guanine. Under physiological conditions, a stable tricyclic glyoxal-DNA adduct is formed through covalent binding to two nitrogens of guanine. Glyoxal is also generated from oxidative stress and lipid peroxidation, contributing to various cellular damage.

Pharmacodynamics

Glyoxal's pharmacodynamic profile involves its capacity to modify proteins and nucleic acids, leading to functional alterations. The formation of AGEs affects cellular mechanisms, resulting in impaired enzyme activity, disrupted metabolism, and reduced cell proliferation. The extent of glycation increases with protein lifespan, making AGEs particularly relevant in chronic conditions associated with aging and metabolic disorders.

Pharmacokinetics

Information regarding the pharmacokinetics of glyoxal, including absorption, distribution, metabolism, and excretion, is not well-defined. Its reactivity suggests that it may have a short half-life in the biological environment, rapidly forming adducts with various biomolecules. Further studies are needed to elucidate its pharmacokinetic properties.

Pregnancy

The safety of glyoxal during pregnancy has not been established. Use with caution and only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unknown whether glyoxal is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from light. Keep container tightly closed.

Mechanism of action

Formaldehyde is thought to act via sensory nerve fibers that signal through the trigeminal nerve to reflexively induce bronchoconstriction through the vagus nerve. Exposure to formaldehyde, a known air toxic, is associated with cancer and lung disease. Despite the adverse health effects of formaldehyde, the mechanisms underlying formaldehyde-induced disease remain largely unknown. Research has uncovered microRNAs (miRNAs) as key posttranscriptional regulators of gene expression that may influence cellular disease state. Although studies have compared different miRNA expression patterns between diseased and healthy tissue, this is the first study to examine perturbations in global miRNA levels resulting from formaldehyde exposure. We investigated whether cellular miRNA expression profiles are modified by formaldehyde exposure to test the hypothesis that formaldehyde exposure disrupts miRNA expression levels within lung cells, representing a novel epigenetic mechanism through which formaldehyde may induce disease. Human lung epithelial cells were grown at air-liquid interface and exposed to gaseous formaldehyde at 1 ppm for 4 hr. Small RNAs and protein were collected and analyzed for miRNA expression using microarray analysis and for interleukin (IL-8) protein levels by enzyme-linked immunosorbent assay (ELISA). RESULTS: Gaseous formaldehyde exposure altered the miRNA expression profiles in human lung cells. Specifically, 89 miRNAs were significantly down-regulated in formaldehyde-exposed samples versus controls. Functional and molecular network analysis of the predicted miRNA transcript targets revealed that formaldehyde exposure potentially alters signaling pathways associated with cancer, inflammatory response, and endocrine system regulation. IL-8 release increased in cells exposed to formaldehyde, and results were confirmed by real-time polymerase chain reaction. Formaldehyde alters miRNA patterns that regulate gene expression, potentially leading to the initiation of a variety of diseases. Formaldehyde at high concentrations is a contributor to air pollution. It is also an endogenous metabolic product in cells, and when beyond physiological concentrations, has pathological effects on neurons. Formaldehyde induces mis-folding and aggregation of neuronal tau protein, hippocampal neuronal apoptosis, cognitive impairment and loss of memory functions, as well as excitation of peripheral nociceptive neurons in cancer pain models. Intracellular calcium ([Ca(2+)](i)) is an important intracellular messenger, and plays a key role in many pathological processes. The present study aimed to investigate the effect of formaldehyde on [Ca(2+)](i) and the possible involvement of N-methyl-D-aspartate receptors (NMDARs) and T-type Ca(2+) channels on the cell membrane. METHODS: Using primary cultured hippocampal neurons as a model, changes of [Ca(2+)](i) in the presence of formaldehyde at a low concentration were detected by confocal laser scanning microscopy. Formaldehyde at 1 mmol/L approximately doubled [Ca(2+)](i). (2R)-amino-5-phosphonopentanoate (AP5, 25 umol/L, an NMDAR antagonist) and mibefradil (MIB, 1 umol/L, a T-type Ca(2+) channel blocker), given 5 min after formaldehyde perfusion, each partly inhibited the formaldehyde-induced increase of [Ca(2+)](i), and this inhibitory effect was reinforced by combined application of AP5 and MIB. When applied 3 min before formaldehyde perfusion, AP5 (even at 50 umol/L) did not inhibit the formaldehyde-induced increase of [Ca(2+)](i), but MIB (1 umol/L) significantly inhibited this increase by 70%. These results suggest that formaldehyde at a low concentration increases [Ca(2+)](i) in cultured hippocampal neurons; NMDARs and T-type Ca(2+) channels may be involved in this process. /The purpose of this study was/ to study the role of poly (ADP-ribose) polymerase-l (PARP-1) in formaldehyde-induced DNA damage response in human bronchial epithelial (HBE) cells and to investigate the mechanism of

Mechanism of action

Glyoxal attacks the amino groups of proteins, nucleotides, and lipids with its highly reactive carbonyl groups. A sequence of non-enzymatic reactions, called glycation, yields stable advanced glycation end-products (AGEs) with a background extent of 0.1-1% of lysine and arginine residues in proteins and 1 in 1.0 X 10-7 nucleotides in DNA. ... Glyoxal forms stable adducts with guanosine by reaction with the N-1 as well as with the exocyclic nitrogen of guanine. The rate of glyoxal-guanine adduct formation is rapid under physiological conditions. A stable tricyclic glyoxal-DNA adduct is formed by covalent binding to two nitrogens of guanine under physiological conditions in vitro. Besides 8-hydroxy-deoxyguanosine, the glyoxal-deoxyguanosine (dG) adduct is one of the major deoxyguanosine oxidation products, being formed by oxygen radicals, lipid peroxidation systems, various types of oxidative stress, and UV irradiation and after in vivo exposure to beta-hydroxy-substituted N-nitrosamines. Glyoxal ... is considered an important intermediate in the formation of advanced glycation end-products (AGEs). AGE modification alters protein function and inactivates enzymes, resulting in disturbance of cellular metabolism, impaired proteolysis, and inhibition of cell proliferation and protein synthesis. The extent of AGE modification increases with the increasing life span of proteins. Consequently, AGEs are especially associated with long-lived proteins, such as collagens, lens crystallins, and neurofilaments, but also have been identified in shorter-lived proteins, including hemoglobin, plasma proteins, lipoproteins, and intracellular proteins. Inhibition studies in bacterial mutagenicity tests demonstrated the production of the reactive oxygen species superoxide, hydrogen peroxide, and singlet oxygen from glyoxal. The mutagenic activity of glyoxal is related to singlet oxygen, as well as to the intracellular GSH level. The hydroxyl radical plays a prominent role in glyoxal-induced DNA cleavage. ... Isolated rat hepatocytes were incubated with different concentrations of glyoxal. Glyoxal by itself was cytotoxic at 5mM, depleted GSH, formed reactive oxygen species (ROS) and collapsed the mitochondrial membrane potential. Glyoxal also induced lipid peroxidation and formaldehyde formation. Glycolytic substrates, eg fructose, sorbitol and xylitol inhibited glyoxal-induced cytotoxicity and prevented the decrease in mitochondrial membrane potential suggesting that mitochondrial toxicity contributed to the cytotoxic mechanism. Glyoxal cytotoxicity was prevented by the glyoxal traps d-penicillamine or aminoguanidine or ROS scavengers were also cytoprotective even when added some time after glyoxal suggesting that oxidative stress contributed to the glyoxal cytotoxic mechanism.